A Phase 1 interventional study of ALN-AGT01 and ALN-AGT01-Matching Placebo in Hypertension, sponsored by Alnylam Pharmaceuticals. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-01-17.
Sponsored by Alnylam Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing irbesartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Irbesartan · Hypertension.
Among the 41 studies testing irbesartan in Hypertension, this one is the 22nd largest by enrollment, is the only one that started in 2019, is the only one in phase 1, and was the 40th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →1 of the 41 studies testing irbesartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Hippocration General Hospital · Sites in Greece
Ages 30–75
By country, each count listing its studies:
Irbesartan: first FDA approval 1997 (AVAPRO), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 11 · Phase 4 21
First in 1995; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 158 across the 41 interventional studies. Of the 35 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 41 have an industry lead sponsor. The 10 most frequent:
Alnylam Pharmaceuticals is the lead sponsor of 84 studies on the registry; 18 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 15 (83%) have results posted.
Alnylam Pharmaceuticals has 7 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 41 studies testing irbesartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of subcutaneous (SC) ALN-AGT01 (zilebesiran) in participants with hypertension. The study will be conducted in 4 parts: Part A will be a single ascending dose (SAD) phase in hypertensive participants, Part B will be a single dose (SD) phase in hypertensive participants with controlled salt intake, Part D will be a MD phase in hypertensive participants who are obese, and Part E will be an open-label SD phase with co-administration of irbesartan in hypertensive patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered a single dose of ALN-AGT01.
Drug: ALN-AGT01
Participants will be administered a single dose of ALN-AGT01-matching placebo.
Drug: ALN-AGT01-Matching Placebo
Participants with controlled salt intake will be administered a single dose of ALN-AGT01.
Drug: ALN-AGT01
Participants with controlled salt intake will be administered a single dose of ALN-AGT01-matching placebo.
Drug: ALN-AGT01-Matching Placebo
Participants, who are obese, will be administered multiple doses of ALN-AGT01 and irbesartan-matching placebo.
Drug: ALN-AGT01 · Drug: Irbesartan-Matching Placebo
Participants, who are obese, will be administered multiple doses of ALN-AGT01-matching placebo and irbesartan.
Drug: ALN-AGT01-Matching Placebo · Drug: Irbesartan
Participants will be administered a single dose of ALN-AGT01 and multiple doses of irbesartan.
Drug: ALN-AGT01 · Drug: Irbesartan
ALN-AGT01 will be administered by subcutaneous (SC) injection.
Also known as: Zilebesiran
Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.
Irbesartan will be administered orally.
Irbesartan-matching placebo will be administered orally.
Number of Participants with Adverse Events (AEs)
Time frame: Parts A, B and E: each up to approximately 12 months; Part D: up to approximately 18 months
Change from Baseline in Blood Angiotensinogen (AGT) Level
Time frame: Parts A, B and E: each up to approximately 12 months; Part D: up to approximately 18 months
Maximum Observed Plasma Concentration (Cmax) of ALN-AGT01 and of Potential Metabolites
Time frame: Parts A, B and E: Up to Day 15; Part D: Up to Day 99
Area Under the Concentration-time Curve (AUC) of ALN-AGT01 and of Potential Metabolites
Time frame: Parts A, B and E: Up to Day 15; Part D: Up to Day 99
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2019 to primary completion in Apr 2022, 35 months.
Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 35 months is above that.
Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zilebesiran · Irbesartan